DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $22.89 billion. The enterprise value is $22.28 billion.
| Market Cap | 22.89B |
| Enterprise Value | 22.28B |
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 385.87 million shares outstanding. The number of shares has decreased by -1.75% in one year.
| Current Share Class | 385.87M |
| Shares Outstanding | 385.87M |
| Shares Change (YoY) | -1.75% |
| Shares Change (QoQ) | -2.09% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 97.10% |
| Float | 383.95M |
Valuation Ratios
The trailing PE ratio is 28.38 and the forward PE ratio is 23.77. DexCom's PEG ratio is 1.19.
| PE Ratio | 28.38 |
| Forward PE | 23.77 |
| PS Ratio | 4.91 |
| Forward PS | 4.30 |
| PB Ratio | 8.31 |
| P/TBV Ratio | 8.63 |
| P/FCF Ratio | 21.24 |
| P/OCF Ratio | 15.88 |
| PEG Ratio | 1.19 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.15, with an EV/FCF ratio of 20.68.
| EV / Earnings | 26.64 |
| EV / Sales | 4.78 |
| EV / EBITDA | 19.15 |
| EV / EBIT | 24.44 |
| EV / FCF | 20.68 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.88 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 1.17 |
| Debt / FCF | 1.30 |
| Interest Coverage | 49.83 |
Financial Efficiency
Return on equity (ROE) is 34.50% and return on invested capital (ROIC) is 33.98%.
| Return on Equity (ROE) | 34.50% |
| Return on Assets (ROA) | 8.89% |
| Return on Invested Capital (ROIC) | 33.98% |
| Return on Capital Employed (ROCE) | 21.72% |
| Weighted Average Cost of Capital (WACC) | 12.13% |
| Revenue Per Employee | $420,000 |
| Profits Per Employee | $75,342 |
| Employee Count | 11,100 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 3.18 |
Taxes
In the past 12 months, DexCom has paid $252.10 million in taxes.
| Income Tax | 252.10M |
| Effective Tax Rate | 23.16% |
Stock Price Statistics
The stock price has decreased by -17.22% in the last 52 weeks. The beta is 1.56, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -17.22% |
| 50-Day Moving Average | 66.59 |
| 200-Day Moving Average | 69.87 |
| Relative Strength Index (RSI) | 34.21 |
| Average Volume (20 Days) | 4,012,177 |
Short Selling Information
The latest short interest is 15.19 million, so 3.94% of the outstanding shares have been sold short.
| Short Interest | 15.19M |
| Short Previous Month | 14.72M |
| Short % of Shares Out | 3.94% |
| Short % of Float | 3.96% |
| Short Ratio (days to cover) | 3.77 |
Income Statement
In the last 12 months, DexCom had revenue of $4.66 billion and earned $836.30 million in profits. Earnings per share was $2.09.
| Revenue | 4.66B |
| Gross Profit | 2.80B |
| Operating Income | 911.80M |
| Pretax Income | 1.09B |
| Net Income | 836.30M |
| EBITDA | 1.16B |
| EBIT | 911.80M |
| Earnings Per Share (EPS) | $2.09 |
Balance Sheet
The company has $2.00 billion in cash and $1.40 billion in debt, giving a net cash position of $602.30 million or $1.56 per share.
| Cash & Cash Equivalents | 2.00B |
| Total Debt | 1.40B |
| Net Cash | 602.30M |
| Net Cash Per Share | $1.56 |
| Equity (Book Value) | 2.75B |
| Book Value Per Share | 7.14 |
| Working Capital | 1.89B |
Cash Flow
In the last 12 months, operating cash flow was $1.44 billion and capital expenditures -$363.50 million, giving a free cash flow of $1.08 billion.
| Operating Cash Flow | 1.44B |
| Capital Expenditures | -363.50M |
| Depreciation & Amortization | 251.80M |
| Net Borrowing | -1.21B |
| Free Cash Flow | 1.08B |
| FCF Per Share | $2.79 |
Margins
Gross margin is 60.10%, with operating and profit margins of 19.56% and 17.94%.
| Gross Margin | 60.10% |
| Operating Margin | 19.56% |
| Pretax Margin | 23.35% |
| Profit Margin | 17.94% |
| EBITDA Margin | 24.96% |
| EBIT Margin | 19.56% |
| FCF Margin | 23.11% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.75% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 3.65% |
| FCF Yield | 4.71% |
Analyst Forecast
The average price target for DexCom is $85.33, which is 43.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $85.33 |
| Price Target Difference | 43.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 10.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 7.06 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.06 |
| Piotroski F-Score | 6 |